GlassScriptPhysician profile
Ma Ahad Athar
NPI 1518166818
$6,809.49
in general payments reported to CMS, 2019-2025
45 companies · $1,882 in 2025
The $1,882 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $173 · 2021: $264 · 2022: $505 · 2023: $1,568 · 2024: $1,783 · 2025: $1,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,210 · Education: $23.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,210.22 |
| Education | $23.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $845.48 | 2022-2025 | Imfinzi, Enhertu, Lynparza |
| Janssen Pharmaceuticals, INC | $701.98 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $545.66 | 2019-2025 | |
| Genzyme Corporation | $429.72 | 2019-2025 | |
| Janssen Biotech, INC. | $364.85 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Gilead Sciences, INC. | $357.21 | 2019-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $338.82 | 2023-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Eisai INC. | $312.17 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $258.58 | 2019-2025 | Vpriv, Vonvendi, Advate |
| Celgene Corporation | $243.49 | 2022-2025 | Reblozyl, Opdualag |
| Pharmaessentia USA Corporation | $235.33 | 2023-2025 | Besremi |
| Lilly USA, LLC | $234.12 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $228.74 | 2023-2025 | Enhertu, Vanflyta |
| E.R. Squibb & Sons, L.L.C. | $222.33 | 2019-2025 | Opdivo |
| Medtronic, INC. | $168.63 | 2023 | Onyx Frontier |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $167.82 | 2023-2025 | |
| Emd Serono, INC. | $154.22 | 2022-2025 | Bavencio |
| Pfizer INC. | $119.99 | 2019-2025 | |
| Amgen INC. | $113.91 | 2022-2023 | Lumakras, Kyprolis |
| Regeneron Healthcare Solutions, INC. | $95.18 | 2023-2025 | Libtayo |
| Allergan, INC. | $86.43 | 2019 | |
| Geron Corporation | $46.38 | 2025 | Rytelo |
| Adc Therapeutics America, INC. | $44.69 | 2025 | |
| Incyte Corporation | $42.21 | 2025 | Monjuvi, Jakafi |
| Caris Mpi, INC. | $39.33 | 2025 | Mi Cancer Seek |
| Astellas Pharma US INC | $38.05 | 2024 | Padcev, Xtandi |
| Myriad Genetic Laboratories, INC. | $36.06 | 2024-2025 | Precisetumor |
| Alexion Pharmaceuticals, INC. | $30.69 | 2024 | Ultomiris |
| Array Biopharma INC | $26.19 | 2025 | Mektovi, Lorbrena, Braftovi |
| Acrotech Biopharma INC. | $23.94 | 2022 | |
| Glaxosmithkline, LLC. | $22.90 | 2022 | |
| Morphosys, US INC. | $22.25 | 2023 | Monjuvi |
| Kite Pharma, INC. | $21.01 | 2021 | |
| Foundation Medicine, INC. | $19.80 | 2023 | |
| Exelixis INC. | $19.75 | 2025 | Cabometyx |
| Tempus Ai, INC | $18.76 | 2025 | Xt Cdx |
| Medtronic USA, INC. | $18.55 | 2019 | |
| Blueprint Medicines Corporation | $17.34 | 2022 | |
| Legend Biotech USA INC. | $15.89 | 2025 | Carvykti |
| Ipsen Biopharmaceuticals, INC | $15.55 | 2023 | Somatuline Depot, Onivyde |
| Recordati_rare_diseases_inc. | $13.52 | 2024 | Sylvant |
| Taiho Oncology, INC. | $13.19 | 2022 | |
| Kyowa Kirin, INC. | $13.16 | 2019 | |
| Novocure INC. | $13.13 | 2022 | |
| Genentech USA, INC. | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ma Athar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.